View Older Stories View More Recent Stories

Jun 18, 2018 05:48AM Bristol-Myers Squibb (BMY) Reports ELOQUENT-3 Trial Phase 2 Study Evaluating Empliciti (elotuzumab) Plus Pomalidomide & Low-Dose Dexamethasone Achieves Primary Endpoint
Jun 17, 2018 06:30AM Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multi
Jun 15, 2018 08:34AM Bristol-Myers Squibb (BMY) Says China National Drug Administration Approved Country’s First Immuno-Oncology Agent, Opdivo, for Previously Treated NSCLC
Jun 15, 2018 08:32AM China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Jun 14, 2018 04:30PM Bristol-Myers Squibb Announces Dividend
Jun 13, 2018 06:00AM Bristol-Myers Squibb to Present New Research Findings on the Treatment of Patients with Early Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)
Jun 11, 2018 04:45PM Bristol-Myers Squibb to Take Part in Goldman Sachs 39th Annual Global Healthcare Conference
Jun 7, 2018 06:59AM Bristol-Myers Squibb to Announce Results for Second Quarter 2018 on July 26
Jun 4, 2018 09:11AM Bristol-Myers Squibb (BMY) Says Opdivo 3 mg/kg Demonstrates Sustained, Superior RFS Versus Yervoy 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma
Jun 4, 2018 09:00AM Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma
Jun 4, 2018 07:16AM Bristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate -227 Trial Evaluating Opdivo (nivolumab) Plus low-dose Yervoy (ipilimumab) & Opdivo plus Chemotherapy
Jun 4, 2018 06:59AM Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD-L1 <1%, in CheckMate -227 Study to Be Presented at ASCO 2018
Jun 4, 2018 05:44AM Bristol-Myers Squibb (BMY) Reports FDA Lifted Partial Clinical Hold on CA209-602 (CheckMate -602) Phase 3 Study Evaluating Opdivo (nivolumab)-based Combination
Jun 1, 2018 06:50PM U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma
Jun 1, 2018 07:00AM Bristol-Myers Squibb (BMY) Says Opdivo Plus Low-Dose Yervoy Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced RCC in
Jun 1, 2018 06:59AM Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal
May 24, 2018 06:59AM Bristol-Myers Squibb to Hold Investor Event to Discuss ASCO Highlights
May 22, 2018 08:00AM Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
May 16, 2018 05:08PM Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO
May 16, 2018 05:07PM Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018
May 15, 2018 06:59AM Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference
May 3, 2018 08:39AM Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic NSCLC
May 3, 2018 08:38AM European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)
May 2, 2018 08:32AM Bristol-Myers Squibb (BMY), Flatiron Health Expand Collaboration with Three-Year Agreement
May 2, 2018 08:30AM Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement
Apr 26, 2018 06:59AM Bristol-Myers Squibb Reports First Quarter Financial Results
Apr 26, 2018 06:59AM Bristol-Myers Squibb Reports First Quarter Financial Results
Apr 25, 2018 04:37PM Bristol-Myers Squibb (BMY) Says EC Approved its Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Apr 25, 2018 04:20PM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Apr 18, 2018 04:19PM Bristol-Myers Squibb (BMY) Says FDA Accepted sBLA for Opdivo in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
Apr 18, 2018 04:15PM U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review
Apr 16, 2018 04:28PM Bristol-Myers Squibb (BMY) Reports Collaboration with Janssen Pharmaceuticals Inc. to Develop & Commercialize Next-Generation Cardiovascular Therapy
Apr 16, 2018 04:15PM Bristol-Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Next-Generation Cardiovascular Therapy
Apr 16, 2018 04:04PM Bristol-Myers Squibb (BMY) Says In CheckMate -141, Opdivo Demonstrated Sustained OS Advantage over Standard of Care in Patients with Recurrent or Metastatic SCCHN
Apr 16, 2018 04:03PM In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Apr 16, 2018 12:52PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Apr 16, 2018 11:41AM FDA approves Bristol-Myers' (BMY) nivolumab plus ipilimumab combination for intermediate or poor-risk advanced RCC
Apr 16, 2018 09:08AM Bristol-Myers Squibb (BMY) Reports Initial Results from Phase 2 Study of CheckMate -227 Evaluating Opdivo Plus Low-Dose Yervoy Combination
Apr 16, 2018 09:05AM Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)
Apr 13, 2018 04:37PM Bristol-Myers Squibb (BMY) Reports Data from Phase 3 CheckMate-078 Trial Evaluating Opdivo (nivolumab) vs. Docetaxel in Predominantly Chinese Population
Apr 13, 2018 04:34PM Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (N
Apr 13, 2018 04:15PM Bristol-Myers Squibb (BMY) and Illumina (ILMN) Announce Pact to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies
Apr 13, 2018 04:15PM Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies
Apr 12, 2018 07:00AM Bristol-Myers Squibb (BMY), Harvard Announce New Fibrosis Research Collaboration
Apr 12, 2018 06:59AM Bristol-Myers Squibb and Harvard Announce New Fibrosis Research Collaboration
Apr 2, 2018 04:30PM Bristol-Myers Squibb to Hold Investor Event to Discuss AACR Highlights
Mar 27, 2018 07:00AM Bristol-Myers Squibb (BMY) Says FDA Accepted its Application for Opdivo Plus Yervoy for Previously Treated Patients with MSI-H or dMMR Metastatic Colorectal Cancer for Priority Review
Mar 27, 2018 06:59AM U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for Previously Treated Patients with MSI-H or dMMR Metastatic Color
Mar 26, 2018 07:11AM Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
Mar 26, 2018 06:59AM Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
View More Recent Stories View Older Stories